All In MedTech

FDA Clearance Tracker · DEN190023

AmplideX Fragile X Dx & Carrier Screen Kit

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 20, 2026Latest source record: Feb 21, 2020 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

Decided

Feb 21, 2020

De Novo granted

Time to decision

309 days

Received Apr 18, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN190023
Device name
AmplideX Fragile X Dx & Carrier Screen Kit
Applicant location
Austin, TX
Received
Apr 18, 2019
Decided
Feb 21, 2020
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 866.5970

Every decision under product code OYV

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Asuragen, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.